FDA Flu Vaccine Oversight Gets Funding Boost Under FY 2005 Approps Bill
This article was originally published in The Pink Sheet Daily
FDA funding to review influenza vaccine production will be increased by $300,000 under the fiscal year omnibus spending bill
You may also be interested in...
FDA hopes that some or all of the excess foreign flu vaccine will be available for U.S. use by year-end, FDA Acting Commissioner Crawford tells Senate subcommittee. FDA should finish reviewing 750,000 doses of foreign vaccine purchased through distribution channels by cities and states in two to three weeks, Crawford says.
Congress’ top priority in strengthening the flu vaccine supply should be funding research in cell-cultured manufacturing, FDA Acting Commissioner Crawford tells Senate committee. However, even with cell-culture technology, flu vaccine market is unlikely to regain all of its previous suppliers, he suggests.
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.